



## **John Curnow Joins Celentyx Ltd as Principal Scientist**

**BIRMINGHAM, UK – 28th September, 2010** - Celentyx Ltd, a pharmaceutical company with a focus on immune system mediated diseases, announced today that Dr John Curnow has been appointed as Principal Scientist.

Dr Curnow brings a wealth of expertise to Celentyx Ltd having a longstanding interest in immunological tolerance and autoimmunity and is a leading expert on human T cells with particular interest in “new” CD4+ T helper subsets (e.g. Tregs, Th17, Th22), studying their impact in both health and disease. His work has been published widely and cited extensively. Dr Curnow is also a Senior Lecturer in the School of Immunity and Infection, which is the site of the prestigious MRC Centre for Immune Regulation at the University of Birmingham Medical School.

"Celentyx Ltd is truly at the forefront of immune disease research," says Dr Curnow. "I'm looking forward to working with the team as I believe that Celentyx's future holds tremendous potential".

"We're delighted to bring John's expertise to Celentyx," says Celentyx's CEO and Founder, Professor Nicholas Barnes. "His high-level expertise on human T-cells will allow Celentyx to provide our clients with even more sophisticated levels of assay design and interpretation for studying these extremely key immune cell subsets and add to our drug development pipeline."

### **About Celentyx Ltd**

Celentyx is a pharmaceutical company focused on developing treatments for diseases of the human immune system.

Using our proprietary Immuno-Profiling™ platform, Celentyx has developed a pipeline of reprofiled drug candidates (ready for Phase II clinical trial) and has created an increasing portfolio of valuable drug targets upon human immune cells relevant for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia).

Our discovery services enable partners to identify new development paths for clinical-stage drug candidates, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system. The company has established partnerships with a number of medium and large pharmaceutical companies.

For more information, please visit Celentyx's website at [www.celentyx.com](http://www.celentyx.com) or contact:

Catherine Brady, PhD

Commercial Manager

E-mail: [catherine.brady@celentyx.com](mailto:catherine.brady@celentyx.com)